Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

Droplet aerosol dissemination of carbapenem-resistant Acinetobacter baumannii surrounding ventilated patients.

Mousa M, Schwartz D, Carmeli Y, Nutman A.

Infect Control Hosp Epidemiol. 2019 Feb 18:1-3. doi: 10.1017/ice.2018.335. [Epub ahead of print]

PMID:
30773156
2.

A five-day course of oral antibiotics followed by faecal transplantation to eradicate carriage of multidrug-resistant Enterobacteriaceae: A Randomized Clinical Trial.

Huttner BD, de Lastours V, Wassenberg M, Maharshak N, Mauris A, Galperine T, Zanichelli V, Kapel N, Bellanger A, Olearo F, Duval X, Armand L, Carmeli Y, Bonten M, Fantin B, Harbarth S; R-Gnosis WP3 study group.

Clin Microbiol Infect. 2019 Jan 4. pii: S1198-743X(18)30796-1. doi: 10.1016/j.cmi.2018.12.009. [Epub ahead of print]

3.

Treatment outcomes of colistin and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial.

Dickstein Y, Lellouche J, Dalak Amar MB, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Benattar YD, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA study group.

Clin Infect Dis. 2018 Nov 20. doi: 10.1093/cid/ciy988. [Epub ahead of print]

PMID:
30462182
4.

Combining VITEK® 2 with colistin agar dilution screening assist timely reporting of colistin susceptibility.

Lellouche J, Schwartz D, Elmalech N, Ben Dalak MA, Temkin E, Paul M, Geffen Y, Yahav D, Eliakim-Raz N, Durante-Mangoni E, Iossa D, Bernardo M, Daikos GL, Skiada A, Pantazatou A, Antoniadou A, Mouton JW, Carmeli Y; AIDA study group.

Clin Microbiol Infect. 2018 Oct 4. pii: S1198-743X(18)30636-0. doi: 10.1016/j.cmi.2018.09.014. [Epub ahead of print]

PMID:
30291971
5.

Carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae and the risk of surgical site infection after colorectal surgery: a prospective cohort study.

Dubinsky-Pertzov B, Temkin E, Harbarth S, Fankhauser-Rodriguez C, Carevic B, Radovanovic I, Ris F, Kariv Y, Buchs NC, Schiffer E, Cohen Percia S, Nutman A, Fallach N, Klausner J, Carmeli Y; R-GNOSIS WP4 study group.

Clin Infect Dis. 2018 Sep 10. doi: 10.1093/cid/ciy768. [Epub ahead of print]

PMID:
30204851
6.

Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study.

Temkin E, Fallach N, Almagor J, Gladstone BP, Tacconelli E, Carmeli Y; DRIVE-AB Consortium.

Lancet Glob Health. 2018 Sep;6(9):e969-e979. doi: 10.1016/S2214-109X(18)30278-X.

7.

Clostridium difficile fecal toxin level is associated with disease severity and prognosis.

Cohen NA, Miller T, Na'aminh W, Hod K, Adler A, Cohen D, Guzner-Gur H, Santo E, Halpern Z, Carmeli Y, Maharshak N.

United European Gastroenterol J. 2018 Jun;6(5):773-780. doi: 10.1177/2050640617750809. Epub 2017 Dec 21.

8.

Success of a National Intervention in Controlling Carbapenem-Resistant Enterobacteriaceae in Israel's Long-Term Care Facilities.

Ben-David D, Masarwa S, Fallach N, Temkin E, Solter E, Carmeli Y, Schwaber MJ; Israel LTCF CRE Working Group.

Clin Infect Dis. 2018 Jul 9. doi: 10.1093/cid/ciy572. [Epub ahead of print]

PMID:
29986007
9.

Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β-lactamase-producing Enterobacteriaceae.

Russo A, Falcone M, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Cisneros JM, Hernández-Torres A, Farcomeni A, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Rodriguez-Gomez J, Souli M, Bonomo RA, Paterson DL, Carmeli Y, Pascual A, Rodríguez-Baño J, Venditti M; REIPI/ESGBIS/INCREMENT investigators.

Int J Antimicrob Agents. 2018 Nov;52(5):577-585. doi: 10.1016/j.ijantimicag.2018.06.018. Epub 2018 Jun 30.

PMID:
29969692
10.

The impact of antibiotic use on transmission of resistant bacteria in hospitals: Insights from an agent-based model.

Almagor J, Temkin E, Benenson I, Fallach N, Carmeli Y; DRIVE-AB consortium.

PLoS One. 2018 May 14;13(5):e0197111. doi: 10.1371/journal.pone.0197111. eCollection 2018.

11.

The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.

Zak-Doron Y, Dishon Benattar Y, Pfeffer I, Daikos GL, Skiada A, Antoniadou A, Durante-Mangoni E, Andini R, Cavezza G, Leibovici L, Yahav D, Eliakim-Raz N, Carmeli Y, Nutman A, Paul M; AIDA Study Group .

Clin Infect Dis. 2018 Nov 28;67(12):1815-1823. doi: 10.1093/cid/ciy371.

PMID:
29718143
12.

Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.

PMID:
29695358
13.

Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.

Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y.

Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1281-1288. doi: 10.1007/s10096-018-3247-1. Epub 2018 Apr 7.

PMID:
29627951
14.

Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing Escherichia coli and ESBL-Producing Klebsiella pneumoniae.

Scheuerman O, Schechner V, Carmeli Y, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale PL, Oliver A, Ruiz-Garbajosa P, Gasch O, Gozalo M, Pitout J, Akova M, Peña C, Molina J, Hernández-Torres A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Karaiskos I, de la Calle C, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Navarro-San Francisco C, Bonomo RA, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT investigators.

Infect Control Hosp Epidemiol. 2018 Jun;39(6):660-667. doi: 10.1017/ice.2018.63. Epub 2018 Apr 5.

PMID:
29618394
15.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
16.

Lessons From an Outbreak of Varicella Infection in Pediatric Hemato-oncology Patients.

Manistarski M, Levin D, Dvir R, Berger-Achituv S, Rosenfeld Keidar H, Grisaru-Soen G, Carmeli Y, Elhasid R.

Pediatr Infect Dis J. 2018 Jul;37(7):649-653. doi: 10.1097/INF.0000000000001920.

PMID:
29373475
17.

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group.

Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21.

PMID:
29276051
18.

Israeli National Policy for Carbapenem-Resistant Enterobacteriaceae Screening, Carrier Isolation and Discontinuation of Isolation.

Solter E, Adler A, Rubinovitch B, Temkin E, Schwartz D, Ben-David D, Masarwa S, Carmeli Y, Schwaber MJ.

Infect Control Hosp Epidemiol. 2018 Jan;39(1):85-89. doi: 10.1017/ice.2017.211. Epub 2017 Dec 15.

PMID:
29241475
19.

Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina Gil-Bermejo J, Hernández A, Venditti M, Prim N, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Paño-Pardo JR, Torre-Cisneros J, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual Á, Rodríguez-Baño J; Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group.

Clin Infect Dis. 2017 Oct 30;65(10):1615-1623. doi: 10.1093/cid/cix606.

20.
21.

Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply.

Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J.

Lancet Infect Dis. 2017 Oct;17(10):1020-1021. doi: 10.1016/S1473-3099(17)30522-4. No abstract available.

PMID:
28948921
22.

Prevalence of anti-hepatitis B surface antibodies among children and adolescents vaccinated in infancy and effect of booster dose administered within a pilot study.

Bassal R, Markovich MP, Weil M, Shinar E, Carmeli Y, Dan M, Sofer D, Mendelson E, Cohen D, Shohat T.

Epidemiol Infect. 2017 Oct;145(14):2890-2895. doi: 10.1017/S0950268817002126. Epub 2017 Sep 14.

PMID:
28903797
23.

Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.

Harris PNA, Pezzani MD, Gutiérrez-Gutiérrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, Venditti M, Tumbarello M, Navarro-Francisco C, Calbo E, Akova M, Giamarellou H, Oliver A, Almirante B, Gasch O, Martínez-Martínez L, Schwaber MJ, Daikos G, Pitout J, Peña C, Hernández-Torres A, Doi Y, Pérez F, Tuon FF, Tacconelli E, Carmeli Y, Bonomo RA, Pascual Á, Paterson DL, Rodríguez-Baño J; ESGBIS/REIPI/INCREMENT Group.

Int J Antimicrob Agents. 2017 Nov;50(5):664-672. doi: 10.1016/j.ijantimicag.2017.08.005. Epub 2017 Aug 3.

PMID:
28782704
24.

Does Acinetobacter baumannii Serve as a Source for blaNDM Dissemination into Enterobacteriaceae in Hospitalized Patients?

Adler A, Glick R, Lifshitz Z, Carmeli Y.

Microb Drug Resist. 2018 Mar;24(2):150-153. doi: 10.1089/mdr.2016.0330. Epub 2017 Jun 30.

PMID:
28665176
25.

Incidence and Risk Factors for Community and Hospital Acquisition of Clostridium difficile Infection in the Tel Aviv Sourasky Medical Center.

Na'amnih W, Adler A, Miller-Roll T, Cohen D, Carmeli Y.

Infect Control Hosp Epidemiol. 2017 Aug;38(8):912-920. doi: 10.1017/ice.2017.82. Epub 2017 May 31.

PMID:
28558856
26.

Evolution and dissemination of the Klebsiella pneumoniae clonal group 258 throughout Israeli post-acute care hospitals, 2008-13.

Adler A, Lifshitz Z, Gordon M, Ben-David D, Khabra E, Masarwa S, Zion O, Schwaber MJ, Carmeli Y.

J Antimicrob Chemother. 2017 Aug 1;72(8):2219-2224. doi: 10.1093/jac/dkx135.

PMID:
28486697
27.

Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Investigators.

Lancet Infect Dis. 2017 Jul;17(7):726-734. doi: 10.1016/S1473-3099(17)30228-1. Epub 2017 Apr 22.

PMID:
28442293
28.

Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control.

Friedman ND, Carmeli Y, Walton AL, Schwaber MJ.

Infect Control Hosp Epidemiol. 2017 May;38(5):580-594. doi: 10.1017/ice.2017.42. Epub 2017 Mar 15. Review. Erratum in: Infect Control Hosp Epidemiol. 2017 Sep;38(9):1136.

PMID:
28294079
29.

Fixed time interval compared with on-demand oral analgesia protocols for post-caesarean pain: a randomised controlled trial.

Yefet E, Taha H, Salim R, Hasanein J, Carmeli Y, Schwartz N, Nachum Z.

BJOG. 2017 Jun;124(7):1063-1070. doi: 10.1111/1471-0528.14546. Epub 2017 Feb 25.

30.
31.

Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Palacios-Baena ZR, Gutiérrez-Gutiérrez B, De Cueto M, Viale P, Venditti M, Hernández-Torres A, Oliver A, Martínez-Martínez L, Calbo E, Pintado V, Gasch O, Almirante B, Antonio Lepe J, Pitout J, Akova M, Peña-Miralles C, Schwaber MJ, Tumbarello M, Tacconelli E, Origüen J, Prim N, Bou G, Giamarellou H, Bermejo J, Hamprecht A, Pérez F, Almela M, Lowman W, Hsueh PR, Navarro-San Francisco C, Torre-Cisneros J, Carmeli Y, Bonomo RA, Paterson DL, Pascual Á, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group.

J Antimicrob Chemother. 2017 Mar 1;72(3):906-913. doi: 10.1093/jac/dkw513.

32.

EpideMiology and control measures of outBreaks due to Antibiotic-Resistant orGanisms in EurOpe (EMBARGO): a systematic review protocol.

Babu Rajendran N, Gladstone BP, Rodríguez-Baño J, Sifakis F, Voss A, Carmeli Y, Burkert FR, Gkolia P, Tacconelli E.

BMJ Open. 2017 Jan 5;7(1):e013634. doi: 10.1136/bmjopen-2016-013634. Erratum in: BMJ Open. 2017 Jan 27;7(1):e013634corr1.

33.

Ceftazidime-Avibactam as Salvage Therapy for Infections Caused by Carbapenem-Resistant Organisms.

Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01964-16. doi: 10.1128/AAC.01964-16. Print 2017 Feb.

34.

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study.

Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT, Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Monnet DL; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group.

Lancet Infect Dis. 2017 Feb;17(2):153-163. doi: 10.1016/S1473-3099(16)30257-2. Epub 2016 Nov 18.

PMID:
27866944
35.

Gentamicin- and Ciprofloxacin-Resistant Enterobacteriaceae in Cattle Farms in Israel: Risk Factors for Carriage and the Effect of Microbiological Methodology on the Measured Prevalence.

Adler A, Sturlesi N, Fallach N, Zilberman-Barzilai D, Hussein O, Blum SE, Klement E, Schwaber MJ, Carmeli Y.

Microb Drug Resist. 2017 Jul;23(5):660-665. doi: 10.1089/mdr.2016.0052. Epub 2016 Nov 9.

PMID:
27828758
36.

Molecular types and antimicrobial susceptibility patterns of Clostridium difficile isolates in different epidemiological settings in a tertiary care center in Israel.

Miller-Roll T, Na'amnih W, Cohen D, Carmeli Y, Adler A.

Diagn Microbiol Infect Dis. 2016 Dec;86(4):450-454. doi: 10.1016/j.diagmicrobio.2016.08.021. Epub 2016 Aug 26.

PMID:
27638350
37.

A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Paño-Pardo JR, Venditti M, Tumbarello M, Daikos G, Pintado V, Doi Y, Tuon FF, Karaiskos I, Machuca I, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J; Investigators from the REIPI/ESGBIS/INCREMENT Group.

Mayo Clin Proc. 2016 Oct;91(10):1362-1371. doi: 10.1016/j.mayocp.2016.06.024. Erratum in: Mayo Clin Proc. 2016 Dec;91(12 ):1843.

PMID:
27712635
38.

Ceftazidime-avibactam in ceftazidime-resistant infections.

Carmeli Y, Armstrong J, Newell P, Stone G, Wardman A.

Lancet Infect Dis. 2016 Sep;16(9):997-998. doi: 10.1016/S1473-3099(16)30265-1. No abstract available.

PMID:
27684334
39.

Evaluation of carriage and environmental contamination by carbapenem-resistant Acinetobacter baumannii.

Nutman A, Lerner A, Schwartz D, Carmeli Y.

Clin Microbiol Infect. 2016 Nov;22(11):949.e5-949.e7. doi: 10.1016/j.cmi.2016.08.020. Epub 2016 Sep 3.

40.

Corrigendum to "Outbreak of adenovirus type 55 infection in Israel" [J. Clin. Virol. 78 (2016) 31-35].

Salama M, Amitai Z, Nutman A, Gottesman-Yekutieli T, Sherbany H, Drori Y, Mendelson E, Carmeli Y, Mandelboim M.

J Clin Virol. 2016 Sep;82:183. doi: 10.1016/j.jcv.2016.06.014. Epub 2016 Jul 18. No abstract available.

PMID:
27523612
41.

Risk Factors for Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae (CP-CRE) Acquisition Among Contacts of Newly Diagnosed CP-CRE Patients.

Schwartz-Neiderman A, Braun T, Fallach N, Schwartz D, Carmeli Y, Schechner V.

Infect Control Hosp Epidemiol. 2016 Oct;37(10):1219-25. doi: 10.1017/ice.2016.153. Epub 2016 Jul 25.

PMID:
27452597
42.

Time to Detection with BacT/Alert FA Plus Compared to BacT/Alert FA Blood Culture Media.

Nutman A, Fisher Even-Tsur S, Shapiro G, Braun T, Schwartz D, Carmeli Y.

Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1469-73. doi: 10.1007/s10096-016-2686-9. Epub 2016 Jun 7.

PMID:
27272123
43.

Correction for Adler et al., Prevalence, Risk Factors, and Transmission Dynamics of Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae: a National Survey of Cattle Farms in Israel in 2013.

Adler A, Sturlesi N, Fallach N, Zilberman-Barzilai D, Hussein O, Blum SE, Klement E, Schwaber MJ, Carmeli Y.

J Clin Microbiol. 2016 Jun;54(6):1671. doi: 10.1128/JCM.00665-16. No abstract available.

44.

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.

Gutiérrez-Gutiérrez B, Pérez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, Viale P, Oliver A, Pintado V, Gasch O, Martínez-Martínez L, Pitout J, Akova M, Peña C, Molina J, Hernández A, Venditti M, Prim N, Origüen J, Bou G, Tacconelli E, Tumbarello M, Hamprecht A, Giamarellou H, Almela M, Pérez F, Schwaber MJ, Bermejo J, Lowman W, Hsueh PR, Mora-Rillo M, Natera C, Souli M, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4159-69. doi: 10.1128/AAC.00365-16. Print 2016 Jul.

45.

Prevalence and risk factors for carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae among patients prior to bowel surgery.

Pfeffer I, Zemel M, Kariv Y, Mishali H, Adler A, Braun T, Klein A, Matalon MK, Klausner J, Carmeli Y, Schwaber MJ.

Diagn Microbiol Infect Dis. 2016 Jul;85(3):377-380. doi: 10.1016/j.diagmicrobio.2016.04.002. Epub 2016 Apr 8.

PMID:
27133560
46.
47.

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium.

BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956.

48.

Dissemination of the blaKPC gene by clonal spread and horizontal gene transfer: comparative study of incidence and molecular mechanisms.

Adler A, Khabra E, Paikin S, Carmeli Y.

J Antimicrob Chemother. 2016 Aug;71(8):2143-6. doi: 10.1093/jac/dkw106. Epub 2016 Apr 12.

PMID:
27073266
49.

Outbreak of adenovirus type 55 infection in Israel.

Salama M, Amitai Z, Amir N, Gottesman-Yekutieli T, Sherbany H, Drori Y, Mendelson E, Carmeli Y, Mandelboim M.

J Clin Virol. 2016 May;78:31-5. doi: 10.1016/j.jcv.2016.03.002. Epub 2016 Mar 4. Erratum in: J Clin Virol. 2016 Sep;82:183.

PMID:
26971165
50.

Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.

Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martínez-Martínez L, Oliver A, Calbo E, Peña C, Akova M, Pitout J, Origüen J, Pintado V, García-Vázquez E, Gasch O, Hamprecht A, Prim N, Tumbarello M, Bou G, Viale P, Tacconelli E, Almela M, Pérez F, Giamarellou H, Cisneros JM, Schwaber MJ, Venditti M, Lowman W, Bermejo J, Hsueh PR, Mora-Rillo M, Gracia-Ahulfinger I, Pascual A, Rodríguez-Baño J; REIPI/ESGBIS/INCREMENT Group.

J Antimicrob Chemother. 2016 Jun;71(6):1672-80. doi: 10.1093/jac/dkv502. Epub 2016 Feb 22.

Supplemental Content

Loading ...
Support Center